These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28123782)

  • 1. Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.
    Fleischmann R; Tongbram V; van Vollenhoven R; Tang DH; Chung J; Collier D; Urs S; Ndirangu K; Wells G; Pope J
    RMD Open; 2017; 3(1):e000371. PubMed ID: 28123782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of TNF-inhibitor plus methotrexate versus oral triple therapy in patients with active rheumatoid arthritis inadequately responding to methotrexate: A meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Int J Clin Pharmacol Ther; 2018 Jun; 56(6):263-269. PubMed ID: 29578394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cycling of tumor necrosis factor inhibitors
    Migliore A; Pompilio G; Integlia D; Zhuo J; Alemao E
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211002682. PubMed ID: 33854570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.
    Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe D; Bombardier C
    BMJ; 2016 Apr; 353():i1777. PubMed ID: 27102806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.
    Cohen S; Wells AF; Curtis JR; Dhar R; Mellors T; Zhang L; Withers JB; Jones A; Ghiassian SD; Wang M; Connolly-Strong E; Rapisardo S; Gatalica Z; Pappas DA; Kremer JM; Saleh A; Akmaev VR
    Rheumatol Ther; 2021 Sep; 8(3):1159-1176. PubMed ID: 34148193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.
    Gulácsi L; Zrubka Z; Brodszky V; Rencz F; Alten R; Szekanecz Z; Péntek M
    Adv Ther; 2019 Mar; 36(3):721-745. PubMed ID: 30637590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
    Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
    BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study.
    Kang EH; Jin Y; Tong AY; Desai RJ; Kim SC
    Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1383-1391. PubMed ID: 31376333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials.
    Mazouyès A; Clay M; Bernard AC; Gaudin P; Baillet A
    Joint Bone Spine; 2017 Oct; 84(5):563-570. PubMed ID: 27989589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
    Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
    Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
    Graudal N; Hubeck-Graudal T; Tarp S; Christensen R; Jürgens G
    PLoS One; 2014; 9(9):e106408. PubMed ID: 25244021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.